In order to improve product quality, Gaowei Group has also introduced advanced production equipment such as medical needle production line, orthopedic material production line, medical catheter production line and prefilled syringe production line from Japan, South Korea, the United States, the Netherlands and Singapore. These highly automated equipments provide a reliable guarantee for standardized production and quality control. In addition, Gaowei Group has also established testing institutions that have reached the international advanced level. The testing center imported advanced testing instruments such as liquid chromatograph and gas chromatograph from Japan and Switzerland. This is the only testing institution in China medical device industry that has been approved by the National Laboratory Accreditation Committee. The test report issued by them has international effect and can be recognized by other countries in the Asia-Pacific region and even the world.
It is these strict quality management and assurance systems that provide a strong guarantee for the production of high-quality products. 1998, Gaowei Group took the lead in passing the ISO9000 quality management system certification in the same industry, 1999 took the lead in passing the EU CE standard certification in the same industry, and the production of blood transfusion equipment products passed the GMP certification. In June 2005, Gaowei Group's "Jerry" trademark was recognized by the State Administration for Industry and Commerce as the first China well-known trademark in China medical device industry; In September 2006, "Jerry" brand disposable infusion medical devices won the title of well-known trademark in China, and "Jerry" brand products were designated as national inspection-free products. Today, "Jerry" has not only won wide acclaim and established a good image among users in 30 provinces, municipalities and autonomous regions, but also sold well in 30 countries and regions such as the United States, Brazil, Germany, Russia, South Africa and India. Cardiac drug stent is a high-tech product for treating coronary heart disease. It delivers the drug stent to the lesion site through interventional surgery to support the narrow blood vessels. For a long time, China's cardiac drug stent market has been dominated by large European and American companies. These companies have mastered the most critical technology, and the product price is extremely expensive, which is unbearable for ordinary patients. After painstaking research, Gaowei Group developed a cardiac drug coating stent with independent intellectual property rights, and creatively changed the drug from spraying to coating. All technical indicators have reached the international advanced level, and the price is about 30% lower than that of foreign products. The appearance of this product broke the long-term monopoly of foreign powerful enterprises on the market of cardiac drug stents in China, and made China get rid of the situation of being controlled by people in the use of this product, greatly reducing the burden on patients.
In Viagra, there are many products with independent intellectual property rights, such as heart drug coated stents. Pre-filled syringe is a kind of high-grade drug packaging material. It is simple and convenient to use by directly storing the liquid medicine in the syringe. At the same time, the syringe itself has good sealing performance, and the medicine can be stored for a long time. This product has been widely used in developed countries such as Europe and America, but it has just started in China, all of which are monopolized by foreign enterprises, and the price remains high. From June 5438, 2005 to October, 2005, Gaowei Group developed prefilled syringes with independent intellectual property rights, which was cheaper than foreign products 10% or more.
Relying on independent innovation to adjust the product structure, seize the commanding heights of technology and adapt to the fiercely competitive market is an important strategic policy of Gaowei Group. In order to keep abreast of the current technological progress and grasp the latest technological trends at home and abroad, the company has strengthened its contact with relevant scientific research institutes, and successively cooperated with scientific research institutes such as Changchun Huaying Institute of China Academy of Sciences, Dalian Institute of Materialization, Beijing 30 1 Hospital, Southwest Hospital of the Third Military Medical University, etc., and established nine R&D centers in different places, with a first-class innovative R&D platform in the industry. Gao Wei also attaches great importance to the construction of talent team and the investment in product research and development. The company spends more than 5% of its sales revenue on new product research and development every year. The company specially invited six academicians from China Academy of Sciences and China Academy of Engineering as consultants; Establish a postdoctoral research center with 9 doctors and postdoctoral fellows; Establish a relationship between talent supply and demand with domestic universities such as Qingdao University of Science and Technology and Sichuan University to attract talents to join; The directional training of industrialized talents in Shanghai Vocational College has formed a one-stop talent introduction and training pattern of technology research and development, product pilot test and industrialization implementation.
In recent years, Gaowei Group has continuously improved its technological innovation system, established four-level technological innovation platforms at national, provincial, municipal and enterprise levels, and strengthened cooperation in Industry-University-Research. Gaowei Group further integrated innovative institutions, strengthened the management of new product research and development, and formulated the "R&D management system", which standardized the whole process of R&D products from product approval to acceptance. The company holds a monthly R&D project report meeting to rationally allocate R&D resources, strengthen planning control and rationally use R&D funds. Disposable hollow fiber plasma separator, type A blood collector, spring self-destructing safety syringe, medical opaque plastic ... Now, Gaowei Group has more than one patented product 100, of which 2 1 has reached the domestic leading level. Strong independent innovation ability and rising level of independent research and development give Gao Wei the right to speak and the initiative to develop in the international market. In 2005, Gao Wei Group took the initiative to contact an American medical device company. After consultation, the two sides reached a cooperative production and marketing agreement on the basis of mutual benefit, and the products were sold by the company as a labeling agent in the United States. This is just one of the measures taken by Gao Wei Group to launch China's national brand in the international market. Facing the market environment of global economic integration, Wei knows that if enterprises do not integrate into the international market, their brand promotion will be restricted and their development will be hindered. Without a place in the international market, it is difficult to establish a national brand. Therefore, in the late 1990 s, Weiwei began to carry out international marketing and actively advanced into the international market. Some merchants and users in more than 20 countries and regions, such as Germany, Britain, Russia, Belgium, the United States, Malaysia and Brazil, have keenly discovered the growth advantages of the "Jerry" brand and ordered "Jerry" products in succession.
After 2000, Gaowei Group further strengthened brand protection at home and abroad, making trademark protection in line with international standards. In China, Gaowei Group began to use the "Jerry" trademark at the beginning of its establishment, and the trademark protection category reached 31; Internationally, trademarks have been registered in 20 countries, including Cuba, Germany, Egypt, France, Russia, Vietnam, Britain and Turkey, which has enabled the sales of "Jerry" brand abroad to enter a stage of rapid growth.
In 20001year, Gao Wei Group formulated a new product export strategy, expanding its original focus on Southeast Asian markets to global markets, focusing on European and African markets, and established a professional export sales team. By strengthening sales in the Middle East, Asia and other markets, they can stabilize big customers, optimize market resources and promote sales in Europe and the United States. Through the business relationship with an Iranian customer, the group won an order for nearly 30 million products from a Bulgarian company. Seize the opportunity of economic development in Russia and other CIS countries, improve the sales of enterprises in the Russian market, radiate neighboring countries and expand the Nordic market extensively. At the same time, they also carry out various forms of cooperation with foreign enterprises, and use labeling production or agency sales to expand overseas trade. Strengthen the internationalization standards of enterprises. In addition to passing the EU CE certification, we have also made great efforts in the US FDA certification. Syringes, syringes, feeders and other products have passed the 5 10K license issued by FDA, clearing the way for the smooth export of products to the United States.
On February 27th, 2004, Gaowei Group Medical Polymer Products Co., Ltd. was successfully listed on the Growth Enterprise Market in Hong Kong, which not only financed the development and production of high-tech products, but also connected with the international community through listing in many ways, and improved the international reputation of enterprises and products. Today, the national brand of Gaowei Group is moving towards the international first-class level.